ArticleCancer immunology, immunotherapy : CII2025

Dual efficacy of tocilizumab in managing PD-1 inhibitors-induced myocardial inflammatory injury and suppressing tumor growth with PD-1 inhibitors: a preclinical study.

Yanxin Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.